Unspecified Adult Solid Tumor, Protocol Specific
Conditions
Keywords
unspecified adult solid tumor, protocol specific
Brief summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of resveratrol may prevent cancer. PURPOSE: This phase I trial is studying the side effects and best dose of resveratrol in preventing cancer in healthy participants.
Detailed description
OBJECTIVES: * Determine the concentration of resveratrol and its metabolites in the plasma, urine, and feces of healthy participants. * Correlate dose with systemic concentration of this drug and its metabolites in these participants. * Determine the safety of this drug in these participants. OUTLINE: This is an open-label, dose-escalation, multicenter study. Beginning 5 days before study drug administration, participants are put on a controlled diet (avoiding all resveratrol-containing food or drink) for washout. Participants receive oral resveratrol once on day 1. Cohorts of 10 participants receive escalating doses of resveratrol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 10 participants experience dose-limiting toxicity. A total of 16 participants are treated at the MTD. Participants are followed at 2 and 7 days. PROJECTED ACCRUAL: A total of 10-40 participants will be accrued for this study within 6 months.
Interventions
DRUGresveratrol
Sponsors
National Cancer Institute (NCI)
Study design
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
DISEASE CHARACTERISTICS: * Healthy participants PATIENT CHARACTERISTICS: Age * 18 to 80 Performance status * WHO 0-1 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count \> 1,500/mm\^3 * Platelet count 120,000-450,000mm\^3 * Hemoglobin 10.5-17.5 g/dL for women OR 11.5-19.0 g/dL for men Hepatic * Bilirubin 0.05-1.2 mg/dL * AST and ALT \< 1.5 times normal Renal * Creatinine normal * Urinalysis normal Other * Not pregnant or nursing * Negative pregnancy test * Fertile participants must use effective contraception * Willing to abstain from ingesting large quantities of resveratrol-containing foods * Willing to spend 24 hours in the hospital * No cancer diagnosis that is currently under treatment, is clinically detectable, or that has been treated within the past 5 years except basal cell or squamous cell skin cancer * No concurrent excessive alcohol intake (\>21 units per week for men; 14 units per week for women) PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Concurrent hormone replace ment therapy allowed * Concurrent oral or depot contraceptives allowed Radiotherapy * Not specified Surgery * Not specified Other * At least 2 weeks since prior and no concurrent vitamin supplements of any type * More than 6 months since prior and no concurrent participation in any other experimental study * No other concurrent chronic medications, including over-the-counter medications, herbal/natural preparations, or dietary supplements * No other concurrent prescribed medication
Countries
United Kingdom, United States
Outcome results
None listed